Atlas of Genetics and Cytogenetics in Oncology and Haematology
Transcription of E2F targets under negative control by DREAM complex
NOTCH1 Intracellular Domain Regulates Transcription
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
Constitutive Signaling by NOTCH1 PEST Domain Mutants
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
Binding of TCF/LEF:CTNNB1 to target gene promoters
Interleukin-4 and Interleukin-13 signaling
Cyclin E associated events during G1/S transition
Cyclin A:Cdk2-associated events at S phase entry
TFAP2 (AP-2) family regulates transcription of cell cycle factors
Expressed in 216 organ(s), highest expression level in thoracic mammary gland
Complete sequencing and characterization of 21,243 full-length human cDNAs.
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation.
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I.
DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein.
Six lysine residues on c-Myc are direct substrates for acetylation by p300.
DNA sequence and analysis of human chromosome 8.
Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer.
The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth.
The ubiquitin-specific protease USP28 is required for MYC stability.
CIP2A inhibits PP2A in human malignancies.
Fbw7 and Usp28 regulate myc protein stability in response to DNA damage.
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
A quantitative atlas of mitotic phosphorylation.
Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
Lysine acetylation targets protein complexes and co-regulates major cellular functions.
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation.
Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells.
A chromosome 12 coding region is juxtaposed to the MYC protooncogene locus in a t(8;12)(q24;q22) translocation in a case of B-cell chronic lymphocytic leukemia.
Tipping the balance: Cdk2 enables Myc to suppress senescence.
System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Toward a comprehensive characterization of a human cancer cell phosphoproteome.
tRNA synthetase counteracts c-Myc to develop functional vasculature.
The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc.
The nucleolar protein GLTSCR2 is an upstream negative regulator of the oncogenic Nucleophosmin-MYC axis.
Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
Novel promoter upstream of the human c-myc gene and regulation of c-myc expression in B-cell lymphomas.
Identification and nucleotide sequence of a human locus homologous to the v-myc oncogene of avian myelocytomatosis virus MC29.
Nucleotide sequence of cloned cDNA of human c-myc oncogene.
Nucleotide sequence analysis of human c-myc locus, chicken homologue, and myelocytomatosis virus MC29 transforming gene reveals a highly conserved gene product.
Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours.
The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.
Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.
Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon.
c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62.
Allele-specific activation of the c-myc gene in an atypical Burkitt's lymphoma carrying the t(2;8) chromosomal translocation 250 kb downstream from c-myc.
c-Raf kinase binds to N-terminal domain of c-Myc.
Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
Cloning of human full-length CDSs in BD Creator(TM) system donor vector.
Transcriptional activator Myc-Max complex
Efficient DNA binding requires dimerization with another bHLH protein. Binds DNA as a heterodimer with MAX (PubMed:9680483). Interacts with TAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A and KDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) with FBXW7(PubMed:25775507, PubMed:17558397). Interacts with PIM2. Interacts with RIOX1. The heterodimer MYC:MAX interacts with ABI1; the interaction may enhance MYC:MAX transcriptional activity. Interacts with TRIM6 (By similarity). Interacts with NPM1; the binary complex is recruited to the promoter of MYC target genes and enhances their transcription (PubMed:25956029). Interacts with CIP2A; leading to the stabilization of MYC (PubMed:17632056).
Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28 but by USP36, due to the lack of interaction between isoform 3 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus (PubMed:25775507,PubMed:17558397). Also polyubiquitinated by the DCX(TRUSS) complex. Ubiquitinated by TRIM6 in a phosphorylation-independent manner (By similarity).
POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the four Yamanaka factors. When combined, these factors are sufficient to reprogram differentiated cells to an embryonic-like state designated iPS (induced pluripotent stem) cells. iPS cells exhibit the morphology and growth properties of ES cells and express ES cell marker genes.
Phosphorylated by PRKDC. Phosphorylation at Ser-329 by PIM2 leads to the stabilization of MYC (By similarity). Phosphorylation at Ser-62 by CDK2 prevents Ras-induced senescence. Phosphorylated at Ser-62 by DYRK2; this primes the protein for subsequent phosphorylation by GSK3B at Thr-58. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome.
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000).
A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1.
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)
ACETYLATION AT LYS-143; LYS-157; LYS-275; LYS-317; LYS-323 AND LYS-371
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-58
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-58; SER-62 AND SER-71
ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-148
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6 AND SER-161
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-58 AND SER-62
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; THR-58; SER-62; SER-71 AND SER-293
SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-52; LYS-143; LYS-148 AND LYS-298
NUCLEOTIDE SEQUENCE [MRNA] OF 1-170 (ISOFORM 1)
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-252
VARIANTS ASP-39; SER-57; ALA-59 AND THR-86
STRUCTURE BY NMR OF 402-434 IN COMPLEX WITH MAX
VARIANTS SER-11; CYS-160; ILE-170 AND VAL-322
Class E basic helix-loop-helix protein 39
Impairs interaction with FBXW7 and subsequent degradation by the proteasome. Impaired inhibition of Ras-induced senescence. Abolishes phosphorylation by DYRK2, and subsequent phosphorylation by GSK3B at Thr-58.
Impairs interaction with FBXW7 and subsequent degradation by the proteasome. Normal inhibition of Ras-induced senescence.
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
The gene represented in this entry is involved in disease pathogenesis. Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.
High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
Precursor T-cell acute lymphoblastic leukemia